logo
Hims & Hers stock plummets after Novo Nordisk ends partnership over 'knock-off' Wegovy

Hims & Hers stock plummets after Novo Nordisk ends partnership over 'knock-off' Wegovy

Fast Company4 hours ago

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health, Inc. (NYSE: HIMS), citing concerns over Hims & Hers' 'knock-off' weight loss drugs. Now, Hims & Hers' shares are plummeting as investors react to the news.
It's the latest update in a somewhat volatile year for Hims & Hers. Just this April, the company's stock spiked after it initially announced a collaboration with Novo Nordisk that allowed Hims & Hers to sell Novo Nordisk's FDA-approved weight loss drug, Wegovy, through its platform. But less than two months later, that partnership is fracturing after Novo Nordisk's claim that Hims & Hers engaged in 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.'
At the time of this writing, HIMS stock is down 32.6% since market open. Here's what to know about the break-up:
The shortage that fueled knock-off Wegovy
Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand name drugs using their active ingredient, semaglutide, and sell them at a lower cost. Hims & Hers was one company that took part in selling a compounded—and non-FDA-approved—version of Wegovy.
Then, this February, the FDA announced that Ozempic and Wegovy were no longer categorized under a shortage. With the brand name drugs fully back on the market, the FDA gave compounders 60 to 90 days to stop making copies of the patented drugs.
At the time, Hims & Hers stated in a regulatory filing that, while it saw pathways to continue offering access to certain compounded GLP-1s after the shortage, it could not 'guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all.' However, an analyst told Reuters that Hims & Hers appeared poised to continue selling compounded semaglutide using 'personalized doses' after the shortage officially ended.
Why is Novo Nordisk cutting ties now?
In the wake of the FDA's shortage notice, Hims & Hers announced in April that it was entering a 'long-term collaboration' with Novo Nordisk to offer Wegovy directly to its consumers. Now, though, Novo Nordisk is breaking off the commitment over claims that Hims & Hers has not acted fast enough to stop selling its compounded GLP-1. Other telehealth companies, like Ro and Noom, have similarly faced criticism for continuing to sell their own compounded GLP-1 despite agreements with Eli Lilly, the maker of Zepbound.
In an email to Fast Company, a Novo Nordisk spokesperson explained that 'semaglutide compounding is permitted under US compounding laws only in rare instances,' adding that other companies it's working with have 'demonstrated a good faith effort to transition patients to authentic, FDA-approved Wegovy.'
However, the spokesperson continued, 'after over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that puts patient safety at risk. This is unacceptable and that is why we have decided to end the collaboration.'
That personalization, involves offering the same drug; however, at different doses.
In a press release published this morning, Novo Nordisk also noted that it is 'deeply concerned' about knock-off drugs 'made with foreign illicit active pharmaceutical ingredients.'
'Based on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China,' the release reads. 'According to a report from the Brookings Institute, FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide, nor has FDA ever reviewed or authorized the quality of the 'semaglutide' they produce.'
Hims & Hers did not immediately respond to Fast Company 's request for comment on Novo Nordisk's claims. On X, Novo Nordisk CEO Andrew Dudam said 'Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.' He went on to say 'We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gilead's HIV Breakthrough
Gilead's HIV Breakthrough

Wall Street Journal

timean hour ago

  • Wall Street Journal

Gilead's HIV Breakthrough

Good news the world can use: The Food and Drug Administration last week approved Gilead Science's twice-a-year shot that is nearly 100% effective in preventing HIV transmission. The breakthrough cracks open the door to ending the HIV pandemic. HIV treatments have come a long way over the last four decades thanks to U.S. pharmaceutical innovation that has built on government-funded research. Gilead's daily antiviral pills can prevent HIV transmission and slow AIDS. While an HIV vaccine remains the Holy Grail, Gilead's new long-lasting injection, lenacapavir, is the next best thing. Gilead tested lenacapavir—which was approved by the FDA in 2022 as a treatment for patients with drug-resistant HIV—in two clinical trials against its daily prophylactic pills. Lenacapavir was 100% effective in preventing HIV in one trial and 96% in the other. While Gilead's pills are highly effective at preventing HIV, many people forget to take them daily. Lenacapavir built on research funded by the National Institutes of Health in the 1980s and '90s on viral proteins. Gilead in the 2000s took the research out of the lab by developing lenacapavir, which binds to key HIV proteins and interferes with several steps in the virus's life cycle. The next step is figuring out how to extend lenacapavir's duration.

HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law
HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law

Business Wire

timean hour ago

  • Business Wire

HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws. Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws. Share If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: Why is Hims & Hers being Investigated? Hims & Hers is a telehealth company that provides consumers access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a 'long-term collaboration' through which Hims & Hers would sell Novo Nordisk's popular weight loss drug Wegovy. The Stock Declines as the Truth is Revealed On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in 'deceptive marketing' and the illegal 'selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' On this news, the price of Hims & Hers stock fell $22.25 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025. Click here for more information: What Can You Do? If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

Stock Movers: Tesla, Circle, Hims
Stock Movers: Tesla, Circle, Hims

Bloomberg

timean hour ago

  • Bloomberg

Stock Movers: Tesla, Circle, Hims

On this episode of Stock Movers: Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Scarlet Fu, Alix Steel, Carol Massar and Tim Stenovec. - Tesla (TSLA) shares climbed after the automaker rolled out its long-promised driverless taxi service to a handful of riders, a modest debut for what Elon Musk sees as a transformative new business line. The first robotaxi trips were limited to a narrow portion of Tesla's hometown of Austin on Sunday, with an employee sitting in the front passenger seat of each vehicle to monitor for safety. The carmaker hand-picked a friendly group of retail investors and social-media influencers to serve as initial riders and live-stream their trips. - Circle (CRCL) shares extended gains for a third consecutive session after the Senate passed stablecoin legislation last week. - Hims & Hers (HIMS) shares dropped following news that Novo Nordisk was scrapping a partnership with the upstart telehealth platform after less than two months. Hims, a telehealth platform, wasn't stepping back enough from its practice of mass marketing off-brand imitations of the weight-loss medicine, Novo executives said. 'The big issue with Hims is that we had an agreement that the mass compounding would stop and unfortunately it didn't stop,' said Ludovic Helfgott, executive vice president of product and portfolio strategy at Novo, in an interview. 'That's why we ended the partnership.' In a post on X, Hims Chief Executive Officer Andrew Dudum called Novo executive comments 'misleading.' He said Novo had been pressuring Hims to 'steer patients to Wegovy regardless of whether it was clinically best for patients.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store